Overview
- Akzo Nobel shareholders would own about 55% of the combined company and Axalta shareholders about 45%, based on a 0.6539 Akzo Nobel share exchange per Axalta share.
- The companies project 2024 pro forma revenue of roughly $17 billion and free cash flow of about $1.5 billion, with net leverage guided to 2.0x–2.5x.
- The merged entity will be domiciled in the Netherlands and move to a sole New York Stock Exchange listing after a brief dual-listing period.
- Leadership plans include a one-tier board chaired by Rakesh Sachdev, CEO Greg Poux-Guillaume, and Deputy CEO Chris Villavarayan, with headquarters in Amsterdam and Philadelphia.
- Shareholder votes are expected in mid-2026, with closing targeted for late 2026 to early 2027 subject to approvals, and Axalta shares jumped about 6.6% in premarket trading on the news.